111.44
price up icon2.32%   2.53
pre-market  Vorhandelsmarkt:  111.48   0.04   +0.04%
loading
Schlusskurs vom Vortag:
$108.91
Offen:
$109.01
24-Stunden-Volumen:
427.37K
Relative Volume:
0.40
Marktkapitalisierung:
$26.79B
Einnahmen:
$2.97B
Nettoeinkommen (Verlust:
$-812.83M
KGV:
-32.81
EPS:
-3.3962
Netto-Cashflow:
$-1.24B
1W Leistung:
+0.71%
1M Leistung:
+4.61%
6M Leistung:
-3.24%
1J Leistung:
+29.46%
1-Tages-Spanne:
Value
$108.55
$111.56
1-Wochen-Bereich:
Value
$108.55
$112.58
52-Wochen-Spanne:
Value
$76.53
$131.49

Biontech Se Adr Stock (BNTX) Company Profile

Name
Firmenname
Biontech Se Adr
Name
Telefon
-
Name
Adresse
-
Name
Mitarbeiter
6,772
Name
Twitter
@BioNTech_Group
Name
Nächster Verdiensttermin
2025-03-10
Name
Neueste SEC-Einreichungen
Name
BNTX's Discussions on Twitter

Vergleichen Sie BNTX mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
BNTX
Biontech Se Adr
111.44 26.60B 2.97B -812.83M -1.24B -3.3962
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
470.13 119.21B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
560.93 59.16B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
325.28 40.57B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
571.23 34.02B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
295.59 29.19B 3.81B -644.79M -669.77M -6.24

Biontech Se Adr Stock (BNTX) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-06-05 Bestätigt H.C. Wainwright Buy
2025-05-29 Eingeleitet Goldman Neutral
2025-03-13 Eingeleitet Citigroup Buy
2025-01-10 Eingeleitet Truist Buy
2024-12-11 Eingeleitet Wells Fargo Overweight
2024-12-02 Bestätigt BMO Capital Markets Outperform
2024-11-19 Eingeleitet Berenberg Buy
2024-11-19 Hochstufung Evercore ISI In-line → Outperform
2024-11-08 Hochstufung Goldman Neutral → Buy
2024-09-24 Hochstufung Morgan Stanley Equal-Weight → Overweight
2024-09-17 Hochstufung Jefferies Hold → Buy
2024-09-16 Hochstufung JP Morgan Underweight → Neutral
2024-08-07 Hochstufung Deutsche Bank Hold → Buy
2024-08-02 Hochstufung HSBC Securities Hold → Buy
2024-05-14 Eingeleitet Evercore ISI In-line
2024-02-23 Eingeleitet BMO Capital Markets Outperform
2024-01-05 Eingeleitet Oppenheimer Perform
2023-12-01 Herabstufung JP Morgan Neutral → Underweight
2023-10-16 Herabstufung HSBC Securities Buy → Hold
2023-07-14 Eingeleitet HSBC Securities Buy
2023-05-17 Hochstufung Redburn Neutral → Buy
2022-12-15 Hochstufung BofA Securities Neutral → Buy
2022-08-17 Eingeleitet Cowen Market Perform
2022-07-13 Hochstufung SVB Leerink Mkt Perform → Outperform
2022-07-06 Fortgesetzt Canaccord Genuity Buy
2022-02-01 Hochstufung Redburn Sell → Neutral
2021-12-16 Eingeleitet Morgan Stanley Equal-Weight
2021-11-10 Hochstufung H.C. Wainwright Neutral → Buy
2021-10-22 Eingeleitet Deutsche Bank Hold
2021-10-07 Eingeleitet Jefferies Hold
2021-08-11 Hochstufung Bryan Garnier Neutral → Buy
2021-07-19 Fortgesetzt Wolfe Research Outperform
2021-06-16 Herabstufung Redburn Neutral → Sell
2021-05-18 Eingeleitet Goldman Neutral
2021-05-11 Herabstufung Bryan Garnier Buy → Neutral
2020-12-01 Herabstufung BofA Securities Buy → Neutral
2020-08-03 Fortgesetzt Berenberg Buy
2020-07-21 Hochstufung BofA Securities Neutral → Buy
2020-06-30 Herabstufung H.C. Wainwright Buy → Neutral
2020-05-19 Hochstufung H.C. Wainwright Neutral → Buy
2020-04-28 Herabstufung BofA/Merrill Buy → Neutral
2020-03-18 Herabstufung JP Morgan Overweight → Neutral
2020-03-09 Eingeleitet H.C. Wainwright Neutral
2020-01-24 Herabstufung SVB Leerink Outperform → Mkt Perform
2020-01-22 Herabstufung UBS Buy → Neutral
2019-11-05 Eingeleitet Wolfe Research Outperform
2019-11-04 Eingeleitet Berenberg Buy
2019-11-04 Eingeleitet BofA/Merrill Buy
2019-11-04 Eingeleitet Canaccord Genuity Buy
2019-11-04 Eingeleitet JP Morgan Overweight
2019-11-04 Eingeleitet SVB Leerink Outperform
2019-11-04 Eingeleitet UBS Buy
Alle ansehen

Biontech Se Adr Aktie (BNTX) Neueste Nachrichten

pulisher
Jul 22, 2025

BioNTech’s New Study on PDAC Treatment: Key Insights for Investors - TipRanks

Jul 22, 2025
pulisher
Jul 20, 2025

BioNTech’s BNT327 Clinical Trial: A New Hope for Small-Cell Lung Cancer? - MSN

Jul 20, 2025
pulisher
Jul 18, 2025

Pfizer and BioNTech’s New Shingles Vaccine Study: What Investors Need to Know - TipRanks

Jul 18, 2025
pulisher
Jul 18, 2025

BioNTech’s BNT327 Trial: A Potential Game-Changer in Lung Cancer Treatment? - TipRanks

Jul 18, 2025
pulisher
Jul 17, 2025

BioNTech’s Promising Lung Cancer Trial: A Potential Game-Changer for NSCLC Treatment - TipRanks

Jul 17, 2025
pulisher
Jul 17, 2025

BioNTech Announces Ryan Richardson to Step Down from the Management Board17.07.25News - Ariva

Jul 17, 2025
pulisher
Jul 16, 2025

BioNTech’s DYNASTY-Breast02 Study: A New Hope for Metastatic Breast Cancer? - TipRanks

Jul 16, 2025
pulisher
Jul 13, 2025

OneDigital Investment Advisors LLC Makes New Investment in BioNTech SE Sponsored ADR (NASDAQ:BNTX) - Defense World

Jul 13, 2025
pulisher
Jul 11, 2025

BioNTech’s Promising Phase III Trial for Recurrent Endometrial Cancer - TipRanks

Jul 11, 2025
pulisher
Jul 11, 2025

BioNTech’s Latest Clinical Trial: A New Hope for Lung Cancer Treatment? - TipRanks

Jul 11, 2025
pulisher
Jul 11, 2025

BioNTech’s Phase II Trial: A Potential Game-Changer in Colorectal Cancer Treatment - TipRanks

Jul 11, 2025
pulisher
Jul 11, 2025

Regeneron and BioNTech’s Promising Lung Cancer Trial: What Investors Need to Know - TipRanks

Jul 11, 2025
pulisher
Jul 11, 2025

BioNTech SE Receives Buy Rating from BMO Capital with $143 Price Target - AInvest

Jul 11, 2025
pulisher
Jul 10, 2025

Genmab and BioNTech’s GEN1056 Study: A New Hope for Advanced Solid Tumors - TipRanks

Jul 10, 2025
pulisher
Jul 10, 2025

Genmab and BioNTech’s Immunoradiotherapy Study: A Potential Game-Changer in Cancer Treatment - TipRanks

Jul 10, 2025
pulisher
Jul 10, 2025

Genmab and BioNTech’s Promising Cancer Trial: A Potential Game-Changer? - TipRanks

Jul 10, 2025
pulisher
Jul 10, 2025

Genmab and BioNTech’s GEN1042 Study: A New Hope for Cancer Treatment? - TipRanks

Jul 10, 2025
pulisher
Jul 10, 2025

BioNTech SE Sponsored ADR (NASDAQ:BNTX) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World

Jul 10, 2025
pulisher
Jul 10, 2025

GAMMA Investing LLC Sells 334 Shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX) - Defense World

Jul 10, 2025
pulisher
Jul 09, 2025

BioNTech’s Phase III Trial: A Potential Game-Changer in Endometrial Cancer Treatment - TipRanks

Jul 09, 2025
pulisher
Jul 08, 2025

Genmab and BioNTech’s Promising Immunoradiotherapy Study for Metastatic Tumors - TipRanks

Jul 08, 2025
pulisher
Jul 08, 2025

Genmab and BioNTech’s Pioneering Cancer Trial: A Potential Game-Changer? - TipRanks

Jul 08, 2025
pulisher
Jul 08, 2025

Genmab and BioNTech’s GEN1056 Study: A Potential Game-Changer in Oncology - TipRanks

Jul 08, 2025
pulisher
Jul 08, 2025

Genmab and BioNTech’s GEN1042 Study: A New Hope in Cancer Treatment - TipRanks

Jul 08, 2025
pulisher
Jul 08, 2025

Genmab and BioNTech’s GEN1042 Study: A Potential Game-Changer in Cancer Treatment - TipRanks

Jul 08, 2025
pulisher
Jul 03, 2025

BioNTech SE’s BNT317 Study: A New Hope for Advanced Solid Tumors - TipRanks

Jul 03, 2025
pulisher
Jul 02, 2025

BioNTech’s BNT151 Study Update: Early Termination and Market Implications - TipRanks

Jul 02, 2025
pulisher
Jul 01, 2025

BioNTech ADR Earns Relative Strength Rating Upgrade - MSN

Jul 01, 2025
pulisher
Jul 01, 2025

Biontech SE’s BNT317 Study: A New Hope for Advanced Solid Tumors - TipRanks

Jul 01, 2025
pulisher
Jun 30, 2025

BioNTech’s Latest Clinical Trial: A New Hope for NSCLC Treatment? - TipRanks

Jun 30, 2025
pulisher
Jun 28, 2025

What is HC Wainwright’s Forecast for BioNTech Q3 Earnings? - Defense World

Jun 28, 2025
pulisher
Jun 27, 2025

BioNTech ADR Gets Relative Strength Rating Upgrade - Investor's Business Daily

Jun 27, 2025
pulisher
Jun 26, 2025

BioNTech’s Promising Phase II Study: A Potential Game-Changer in Cancer Treatment - TipRanks

Jun 26, 2025
pulisher
Jun 26, 2025

BioNTech SE’s Promising Study on Pancreatic Cancer Treatment: What Investors Need to Know - TipRanks

Jun 26, 2025
pulisher
Jun 24, 2025

BioNTech’s BNT327: A Promising Phase II Trial for Small-Cell Lung Cancer - TipRanks

Jun 24, 2025
pulisher
Jun 20, 2025

CureVac Soars 41% in a Month on a $1.25B Buyout Offer From BioNTech - Zacks Investment Research

Jun 20, 2025
pulisher
Jun 19, 2025

Equities Analysts Issue Forecasts for BioNTech Q4 Earnings - Defense World

Jun 19, 2025
pulisher
Jun 19, 2025

BioNTech (BNTX) – Analysts’ Recent Ratings Changes - Defense World

Jun 19, 2025
pulisher
Jun 18, 2025

Private-Public Deal Momentum Grows, Yet Megamergers Stay Elusive - Investing.com

Jun 18, 2025
pulisher
Jun 18, 2025

HC Wainwright Estimates BioNTech’s Q4 Earnings (NASDAQ:BNTX) - Defense World

Jun 18, 2025
pulisher
Jun 17, 2025

Market Update: Abercrombie & Fitch Co (ANF) Sees Positive Movement, Closing at 75.00 - DWinneX

Jun 17, 2025
pulisher
Jun 17, 2025

Gaining Ground: fuboTV Inc (FUBO) Closes Higher at 3.26, Up 2.84 - DWinneX

Jun 17, 2025
pulisher
Jun 17, 2025

Market Resilience: Nerdy Inc (NRDY) Finishes Strong at 1.63, Up 2.52 - DWinneX

Jun 17, 2025
pulisher
Jun 16, 2025

5 Stocks To Ride The German Market RallyCureVac (NASDAQ:CVAC), BioNTech (NASDAQ:BNTX) - Benzinga

Jun 16, 2025
pulisher
Jun 12, 2025

Riding the Waves: A Guide to Investing in ARBE Stock - investchronicle.com

Jun 12, 2025
pulisher
Jun 12, 2025

BMY Reports Positive Data On Sotyktu From Arthritis Study - Barchart.com

Jun 12, 2025
pulisher
Jun 12, 2025

Erasca Inc (ERAS) Stock: 52-Week Performance Insights and Trading Volume - investchronicle.com

Jun 12, 2025
pulisher
Jun 12, 2025

CureVac stock soars about 30% after BioNTech agrees to acquire co By Investing.com - Investing.com South Africa

Jun 12, 2025
pulisher
Jun 10, 2025

Vaccine stocks muted as investors assess Kennedy’s overhaul of key panel - The Globe and Mail

Jun 10, 2025
pulisher
Jun 10, 2025

Robert Kennedy Jr Axes Entire CDC Vaccine Panel To 'Restore Public Trust' — Pfizer, Moderna, Other Biotech Stocks Drop In After-Hours Trading - Benzinga

Jun 10, 2025
pulisher
Jun 06, 2025

BMY Collaborates for Oncology Drug: Will This Boost Its Portfolio? - The Globe and Mail

Jun 06, 2025

Finanzdaten der Biontech Se Adr-Aktie (BNTX)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
biotechnology ONC
$295.59
price up icon 1.25%
$26.54
price up icon 0.76%
$102.92
price up icon 0.14%
$571.23
price up icon 0.90%
$36.10
price up icon 1.26%
Kapitalisierung:     |  Volumen (24h):